Log in

OTCMKTS:ORGS - Orgenesis Stock Price, Forecast & News

+0.05 (+1.79 %)
(As of 12/16/2019 07:30 AM ET)
Today's Range
Now: $2.85
50-Day Range
MA: $3.13
52-Week Range
Now: $2.85
Volume26,384 shs
Average Volume31,630 shs
Market Capitalization$46.06 million
P/E RatioN/A
Dividend YieldN/A
Orgenesis Inc is a regenerative therapy company. The Company operates through two segments: Contract Development and Manufacturing Organization (CDMO) and Cellular Therapy Business (CTB). The CDMO activity is operated by the Company's subsidiary, MaSTherCell SA, which specializes in cell therapy development for advanced medicinal products. MaSTherCell is providing two types of services to its customers: process and assay development services and good manufacturing practice (GMP) contract manufacturing services. Read More…

Industry, Sector and Symbol

Industry N/A
Current SymbolOTCMKTS:ORGS
Previous SymbolNASDAQ:ORGS



Sales & Book Value

Annual SalesN/A



Market Cap$46.06 million
Next Earnings Date2/12/2020 (Estimated)
OptionableNot Optionable

Receive ORGS News and Ratings via Email

Sign-up to receive the latest news and ratings for ORGS and its competitors with MarketBeat's FREE daily newsletter.

Orgenesis (OTCMKTS:ORGS) Frequently Asked Questions

What is Orgenesis' stock symbol?

Orgenesis trades on the OTCMKTS under the ticker symbol "ORGS."

How were Orgenesis' earnings last quarter?

Orgenesis Inc (OTCMKTS:ORGS) posted its earnings results on Thursday, November, 7th. The company reported $0.44 earnings per share for the quarter. The firm had revenue of $9.12 million for the quarter. View Orgenesis' Earnings History.

When is Orgenesis' next earnings date?

Orgenesis is scheduled to release their next quarterly earnings announcement on Wednesday, February 12th 2020. View Earnings Estimates for Orgenesis.

What price target have analysts set for ORGS?

2 analysts have issued 12 month target prices for Orgenesis' shares. Their forecasts range from $9.00 to $9.00. On average, they expect Orgenesis' share price to reach $9.00 in the next year. This suggests a possible upside of 215.8% from the stock's current price. View Analyst Price Targets for Orgenesis.

What is the consensus analysts' recommendation for Orgenesis?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Orgenesis in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Orgenesis.

Has Orgenesis been receiving favorable news coverage?

Media stories about ORGS stock have been trending somewhat negative this week, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Orgenesis earned a news sentiment score of -1.7 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Orgenesis.

What other stocks do shareholders of Orgenesis own?

Who are Orgenesis' key executives?

Orgenesis' management team includes the folowing people:
  • Vered Caplan, Chairman of the Board, Chief Executive Officer, President; Chief Executive Officer of Orgenesis Maryland Inc. (Age 46)
  • Neil T. Reithinger CPA, Chief Financial Officer, Treasurer, Secretary (Age 46)
  • Sarah Ferber Ph.D., Chief Scientific Officer (Age 60)
  • Yaron Adler, Director (Age 44)
  • Hugues Bultot, Director
  • David Sidransky M.D., Director (Age 57)
  • Guy Yachin, Director (Age 47)

Who are Orgenesis' major shareholders?

Orgenesis' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Phoenix Holdings Ltd. (0.40%). View Institutional Ownership Trends for Orgenesis.

Which major investors are buying Orgenesis stock?

ORGS stock was bought by a variety of institutional investors in the last quarter, including Phoenix Holdings Ltd.. View Insider Buying and Selling for Orgenesis.

How do I buy shares of Orgenesis?

Shares of ORGS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Orgenesis' stock price today?

One share of ORGS stock can currently be purchased for approximately $2.85.

How big of a company is Orgenesis?

Orgenesis has a market capitalization of $46.06 million. View Additional Information About Orgenesis.

What is Orgenesis' official website?

The official website for Orgenesis is http://www.orgenesis.com/.

How can I contact Orgenesis?

Orgenesis' mailing address is 20271 Goldenrod Lane, Germantown MD, 20876. The company can be reached via phone at 480-659-6404 or via email at [email protected]

MarketBeat Community Rating for Orgenesis (OTCMKTS ORGS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  39 (Vote Outperform)
Underperform Votes:  46 (Vote Underperform)
Total Votes:  85
MarketBeat's community ratings are surveys of what our community members think about Orgenesis and other stocks. Vote "Outperform" if you believe ORGS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ORGS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel